Upload Avatar (500 x 500)
Weihua Xiao
Basic Medical Sciences
University of Science and Technology of China
Anhui
Language: English, Chinese
Immunotherapy
Technology
Product Development
Research
Biotechnology
Immune System
Cancer Treatment
Antibody Engineering
Cell Therapy
Biomedical Engineering
Areas of Focus
- Research and development of immunotherapy technologies and products
Work Experience
- 1985-1995 - Changchun Institute of Biological Products - Assistant Researcher in Applied Molecular Biology
- 1995-1998 - University of Maryland - Postdoctoral Researcher at the Tumor Research Center
- 1998-2004 - National Cancer Institute, USA - Researcher
- 2004-present - University of Science and Technology of China - Professor at the School of Life Sciences
Publications
- Development of an antibody-ligand fusion protein scFvCD16A-sc4-1BBL in Komagataella phaffii with stimulatory activity for Natural Killer cells, Yangyang Li, Siqi Xie, Minhua Chen, Hao Li, Yehai Wang, Yan Fan, Kang An, Yu Wu and Weihua Xiao, 2023
- Advances in NK cell production, Fang F, Xie S, Chen M, Li Y, Yue J, Ma J, Shu X, He Y, Xiao W, Tian Z, 2022
- Anti-Tumor Activity of Expanded PBMC-Derived NK Cells by Feeder-Free Protocol in Ovarian Cancer, Chen, M.; Li, Y.; Wu, Y.; Xie, S.; Ma, J.; Yue, J.; Lv, R.; Tian, Z.; Fang, F.; Xiao, W., 2021
- Development of IL-15/IL-15Rα sushi domain-IgG4 Fc complexes in Pichia pastoris with potent activities and prolonged half-lives, Huan Xu, Mingyang Shi, Changsheng Shao, Hao Li, Jing Wu, Yin Yu, Fang Fang, Yugang Guo, Weihua Xiao, 2021
- BCAP Regulates Dendritic Cell Maturation Through the Dual-Regulation of NF-κB and PI3K/AKT Signaling During Infection, Miao Y, Jiang M, Qi L, Yang, Xiao W, Fang F, 2020
- SHQ1 is an ER stress response gene that facilitates chemotherapeutics-induced apoptosis via sensitizing ER-stress response, Huimin Liu, Siqi Xie, Fang Fang, Dhananjaya V. Kalvakolanu and Weihua Xiao, 2020
